Advertisement

---

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

[2013-06-14] - Results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of PRADAXA 150mg twice daily in patients with non-valvular atrial fibrillation


Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC

[2013-06-03] - - Data accepted as late-breaking, oral presentation at ASCO 2013
- Presentation to include results from secondary endpoint of overall survival
Oral Abstract: #LBA8011
Presentation: Monday, June 3 | Time: 10:45 - 11:15 AM CDT
For U.S. Media Only


Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion

[2013-05-17] - Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray will become the only available short-acting bronchodilator offering two different medicines in a single inhaler


Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference

[2013-05-17] - Data on investigational compounds and an approved product will be presented


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers